• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

研究一种结合两种聚合物的新型人工泪液配方的潜在益处。

Investigating the potential benefits of a new artificial tear formulation combining two polymers.

作者信息

Simmons Peter A, Vehige Joseph G

机构信息

Allergan plc, Irvine, CA, USA.

出版信息

Clin Ophthalmol. 2017 Sep 12;11:1637-1642. doi: 10.2147/OPTH.S135550. eCollection 2017.

DOI:10.2147/OPTH.S135550
PMID:28979093
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5602465/
Abstract

PURPOSE

Artificial tear formulations typically contain a water-soluble polymer to enhance residence time, moisture retention, and binding to the mucin coat of the ocular surface, which facilitate corneal healing. This study investigated the potential advantages of combining carboxymethylcellulose (CMC) and hyaluronic acid (HA) polymers in a single formulation.

MATERIALS AND METHODS

Individual CMC and HA solutions were prepared and tested for bulk viscosity in comparison to a solution that combined CMC and HA. Rheometry determined the differences between solutions at increasing shear rates, simulating eye movement and blinking.

RESULTS

The bulk viscosity of the individual 0.5% CMC and 0.1% HA solutions was 2.5 and 5.7 cP, respectively. The viscosity of the combined solution (13.1 cP) was 60% higher than predicted by additive effects. Rheometry revealed shear rates between 10/second (open eye) and 10,000/second (blinking eye). At these rates, viscosity ranged from 2.7 to 3.5 cP for 0.5% CMC, 2.8 to 6.8 cP for 0.1% HA, and 5.2 to 15.3 cP for the 0.5% CMC-0.1% HA combination. Low-shear viscosity of the CMC-HA combination increased 48% over the sum of the individual solutions, but high-shear viscosity remained virtually unchanged. Data from CMC and HA solutions at higher concentrations were consistent with these results.

CONCLUSION

Combining CMC and HA polymers produced a synergistic increase in low-shear viscosity (which cannot be fully explained by simple molecular entanglement), while the high-shear viscoelasticity of the combined solution remained unaffected. These data suggest that CMC-HA combinations have properties that may be used to formulate artificial tears that optimize ocular retention (through higher low-shear viscosity), while minimizing blur and stickiness during blinking (through lower high-shear viscosity).

摘要

目的

人工泪液制剂通常含有一种水溶性聚合物,以延长停留时间、保持水分并与眼表的黏蛋白层结合,从而促进角膜愈合。本研究调查了在单一制剂中联合使用羧甲基纤维素(CMC)和透明质酸(HA)聚合物的潜在优势。

材料与方法

制备了单独的CMC和HA溶液,并与将CMC和HA混合的溶液进行了总体粘度测试。流变学测定了在增加剪切速率时各溶液之间的差异,模拟了眼球运动和眨眼。

结果

单独的0.5% CMC溶液和0.1% HA溶液的总体粘度分别为2.5和5.7厘泊。混合溶液的粘度(13.1厘泊)比加和效应预测的高60%。流变学显示剪切速率介于10/秒(睁眼)和10000/秒(眨眼)之间。在这些速率下,0.5% CMC的粘度范围为2.7至3.5厘泊,0.1% HA的粘度范围为2.8至6.8厘泊,0.5% CMC - 0.1% HA混合物的粘度范围为5.2至15.3厘泊。CMC - HA混合物的低剪切粘度比各单独溶液的总和增加了48%,但高剪切粘度几乎保持不变。更高浓度的CMC和HA溶液的数据与这些结果一致。

结论

联合使用CMC和HA聚合物可使低剪切粘度协同增加(这不能完全由简单的分子缠结来解释),而混合溶液的高剪切粘弹性不受影响。这些数据表明,CMC - HA混合物具有一些特性,可用于配制人工泪液,通过更高的低剪切粘度优化眼部滞留,同时通过更低的高剪切粘度使眨眼期间的模糊和粘性最小化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09a8/5602465/98f47c11f22f/opth-11-1637Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09a8/5602465/eae7805bdc84/opth-11-1637Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09a8/5602465/58372f8d6d67/opth-11-1637Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09a8/5602465/98f47c11f22f/opth-11-1637Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09a8/5602465/eae7805bdc84/opth-11-1637Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09a8/5602465/58372f8d6d67/opth-11-1637Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/09a8/5602465/98f47c11f22f/opth-11-1637Fig3.jpg

相似文献

1
Investigating the potential benefits of a new artificial tear formulation combining two polymers.研究一种结合两种聚合物的新型人工泪液配方的潜在益处。
Clin Ophthalmol. 2017 Sep 12;11:1637-1642. doi: 10.2147/OPTH.S135550. eCollection 2017.
2
Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study.评价一种增强黏度的人工泪液治疗中重度干眼的多中心、双盲、随机 30 天研究。
Cont Lens Anterior Eye. 2019 Aug;42(4):443-449. doi: 10.1016/j.clae.2018.12.003. Epub 2018 Dec 17.
3
Safety and Efficacy of a Preservative-Free Artificial Tear Containing Carboxymethylcellulose and Hyaluronic Acid for Dry Eye Disease: A Randomized, Controlled, Multicenter 3-Month Study.含羧甲基纤维素和透明质酸的无防腐剂人工泪液治疗干眼病的安全性和有效性:一项随机、对照、多中心3个月研究。
Clin Ophthalmol. 2020 Oct 1;14:2951-2963. doi: 10.2147/OPTH.S256480. eCollection 2020.
4
Physicochemical Properties of Hyaluronic Acid-Based Lubricant Eye Drops.基于透明质酸的润滑眼药水的物理化学性质
Transl Vis Sci Technol. 2019 Nov 1;8(6):2. doi: 10.1167/tvst.8.6.2. eCollection 2019 Nov.
5
Management of post-LASIK dry eye: a multicenter randomized comparison of a new multi-ingredient artificial tear to carboxymethylcellulose.准分子激光原位角膜磨镶术后干眼的管理:一种新型多成分人工泪液与羧甲基纤维素的多中心随机对照研究
Clin Ophthalmol. 2018 May 7;12:839-848. doi: 10.2147/OPTH.S163744. eCollection 2018.
6
Evaluation of a Novel Artificial Tear in the Prevention and Treatment of Dry Eye in an Animal Model.一种新型人工泪液在动物模型中预防和治疗干眼的评估。
J Ocul Pharmacol Ther. 2015 Nov;31(9):525-30. doi: 10.1089/jop.2015.0042. Epub 2015 Aug 31.
7
Osmoprotectants, carboxymethylcellulose and hyaluronic acid multi-ingredient eye drop: a randomised controlled trial in moderate to severe dry eye.渗透保护剂、羧甲基纤维素和透明质酸多成分滴眼液:中重度干眼的随机对照试验
Eye (Lond). 2017 Oct;31(10):1409-1416. doi: 10.1038/eye.2017.73. Epub 2017 Apr 28.
8
Clinical performance of a mid-viscosity artificial tear for dry eye treatment.一种用于治疗干眼症的中等粘度人工泪液的临床性能。
Cornea. 2007 Apr;26(3):294-302. doi: 10.1097/ICO.0b013e31802e1e04.
9
Enhancement of the mydriatic response to tropicamide by bioadhesive polymers.生物黏附聚合物增强托吡卡胺的散瞳反应
J Ocul Pharmacol Ther. 2000 Oct;16(5):419-28. doi: 10.1089/jop.2000.16.419.
10
The role of high molecular weight hyaluronic acid in mucoadhesion on an ocular surface model.高分子量透明质酸在眼部表面模型中的黏膜黏附作用。
J Mech Behav Biomed Mater. 2023 Jul;143:105908. doi: 10.1016/j.jmbbm.2023.105908. Epub 2023 May 15.

引用本文的文献

1
Assessment of the ability of Pseudomonas aeruginosa and Staphylococcus aureus to create biofilms during wound healing in a rat model treated with carboxymethyl cellulose/carboxymethyl chitosan hydrogel containing EDTA.评估在含 EDTA 的羧甲基纤维素/羧甲基壳聚糖水凝胶处理的大鼠模型中,铜绿假单胞菌和金黄色葡萄球菌在伤口愈合过程中形成生物膜的能力。
Int Wound J. 2024 May;21(5):e14878. doi: 10.1111/iwj.14878.
2
Viscoelasticity of Liposomal Dispersions.脂质体分散体的粘弹性。
Nanomaterials (Basel). 2023 Aug 15;13(16):2340. doi: 10.3390/nano13162340.
3
A Critical Appraisal of the Physicochemical Properties and Biological Effects of Artificial Tear Ingredients and Formulations.

本文引用的文献

1
Osmoprotectants, carboxymethylcellulose and hyaluronic acid multi-ingredient eye drop: a randomised controlled trial in moderate to severe dry eye.渗透保护剂、羧甲基纤维素和透明质酸多成分滴眼液:中重度干眼症的随机对照试验
Eye (Lond). 2017 Oct;31(10):1512. doi: 10.1038/eye.2017.124.
2
Viscoelastic Properties of Hyaluronan in Physiological Conditions.生理条件下透明质酸的粘弹性特性
F1000Res. 2015 Aug 25;4:622. doi: 10.12688/f1000research.6885.1. eCollection 2015.
3
Effect of a hyaluronic acid and carboxymethylcellulose ophthalmic solution on ocular comfort and tear-film instability after cataract surgery.
人工泪液成分和配方的物理化学性质及生物学效应的批判性评价。
Int J Mol Sci. 2023 Feb 1;24(3):2758. doi: 10.3390/ijms24032758.
4
Cellulosic Polymers for Enhancing Drug Bioavailability in Ocular Drug Delivery Systems.用于提高眼部药物递送系统中药物生物利用度的纤维素聚合物
Pharmaceuticals (Basel). 2021 Nov 22;14(11):1201. doi: 10.3390/ph14111201.
5
Recent Developments of Carboxymethyl Cellulose.羧甲基纤维素的最新进展
Polymers (Basel). 2021 Apr 20;13(8):1345. doi: 10.3390/polym13081345.
6
Impact of corneal refractive surgery on the precorneal tear film.角膜屈光手术对角膜前泪膜的影响。
Indian J Ophthalmol. 2020 Dec;68(12):2804-2812. doi: 10.4103/ijo.IJO_2296_19.
7
Safety and Efficacy of a Preservative-Free Artificial Tear Containing Carboxymethylcellulose and Hyaluronic Acid for Dry Eye Disease: A Randomized, Controlled, Multicenter 3-Month Study.含羧甲基纤维素和透明质酸的无防腐剂人工泪液治疗干眼病的安全性和有效性:一项随机、对照、多中心3个月研究。
Clin Ophthalmol. 2020 Oct 1;14:2951-2963. doi: 10.2147/OPTH.S256480. eCollection 2020.
8
Physicochemical Properties of Hyaluronic Acid-Based Lubricant Eye Drops.基于透明质酸的润滑眼药水的物理化学性质
Transl Vis Sci Technol. 2019 Nov 1;8(6):2. doi: 10.1167/tvst.8.6.2. eCollection 2019 Nov.
9
Effect of Refresh Plus preservative-free lubricant eyedrops on tear ferning patterns in dry eye and normal eye subjects.Refresh Plus无防腐剂润滑眼药水对干眼和正常眼受试者泪液蕨样形态的影响。
Clin Ophthalmol. 2019 Jun 14;13:1011-1017. doi: 10.2147/OPTH.S213365. eCollection 2019.
10
Cross-linked hyaluronic acid gel occlusive device for the treatment of dry eye syndrome.用于治疗干眼综合征的交联透明质酸凝胶封闭装置
Clin Ophthalmol. 2018 Nov 8;12:2277-2283. doi: 10.2147/OPTH.S187963. eCollection 2018.
透明质酸和羧甲基纤维素眼药水对白内障手术后眼部舒适度和泪膜稳定性的影响。
J Cataract Refract Surg. 2015 Aug;41(8):1699-704. doi: 10.1016/j.jcrs.2014.12.056.
4
Efficacy and safety of two new formulations of artificial tears in subjects with dry eye disease: a 3-month, multicenter, active-controlled, randomized trial.两种新型人工泪液制剂治疗干眼症受试者的疗效和安全性:一项为期3个月的多中心、活性对照、随机试验。
Clin Ophthalmol. 2015 Apr 15;9:665-75. doi: 10.2147/OPTH.S78184. eCollection 2015.
5
Efficacy of 0.18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease.0.18%低渗透明质酸钠眼药水治疗干眼疾病体征和症状的疗效
J Fr Ophtalmol. 2012 Jun;35(6):412-9. doi: 10.1016/j.jfo.2011.07.017. Epub 2012 Apr 6.
6
Randomized, phase III study comparing osmoprotective carboxymethylcellulose with sodium hyaluronate in dry eye disease.一项比较渗透保护羧甲基纤维素与透明质酸钠治疗干眼病的随机III期研究。
Eur J Ophthalmol. 2012 Sep-Oct;22(5):751-61. doi: 10.5301/ejo.5000117.
7
Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease.透明质酸钠和羧甲基纤维素治疗轻中度干眼的疗效。
Cornea. 2011 Feb;30(2):175-9. doi: 10.1097/ICO.0b013e3181e9adcc.
8
Effects of osmoprotection on symptoms, ocular surface damage, and tear film modifications caused by glaucoma therapy.渗透保护对青光眼治疗引起的症状、眼表损伤和泪膜改变的影响。
Eur J Ophthalmol. 2011 May-Jun;21(3):243-50. doi: 10.5301/EJO.2010.5730.
9
Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena).0.18% 透明质酸钠滴眼液(海露,瑞嘉)治疗干眼症的疗效验证。
Am J Ophthalmol. 2010 Apr;149(4):594-601. doi: 10.1016/j.ajo.2009.09.023.
10
Final report of the safety assessment of hyaluronic acid, potassium hyaluronate, and sodium hyaluronate.透明质酸、透明质酸钾和透明质酸钠安全性评估的最终报告。
Int J Toxicol. 2009 Jul-Aug;28(4 Suppl):5-67. doi: 10.1177/1091581809337738.